InsiderClue
Stocks · Health care · Services-Commercial Physical & Biological Research

bioAffinity Technologies, Inc.

BIAF Clue Score58
United States Fiscal year ends December CIK 0001712762
$4.73 -16.22% Close, 9 Oct 2026
Alert on the numbers Alert on insider trades
Price $4.73 +257.95% Close, 9 Oct 2026

Closing prices at the end of each trading day, from 1 Sep 2022. Not a live quote. Adjusted for share splits, so the line has no step at a split; dividends are not added back.

Revenue and profit

What the business sells, and what is left of it. Point at a year for the detail.
RevenueOperating incomeNet income
Fiscal year 2021Operating income−2.2Net income−6.3Fiscal year 2022Revenue0.0Operating income−4.0Net income−8.2EPS, diluted−1.81Fiscal year 2023Revenue2.5 +52,627.4%Operating income−8.0Net income−7.9EPS, diluted−0.91Fiscal year 2024Revenue9.4 +269.7%Operating income−9.0Net income−9.0EPS, diluted−22.50Fiscal year 2025Revenue6.2 −34.2%Operating income−10.6Net income−14.9EPS, diluted−8.66
FY2021FY2022FY2023FY2024FY2025
Revenue n/a 0.0 2.5 9.4 6.2
Growth +52,627.4% +269.7% −34.2%
Operating income −2.2 −4.0 −8.0 −9.0 −10.6
Net income −6.3 −8.2 −7.9 −9.0 −14.9
Growth
EPS, diluted n/a −1.81 −0.91 −22.50 −8.66

Margins

How much of each dollar of revenue it keeps. Point at a year for the detail.
Gross marginOperating marginNet margin
Fiscal year 2021Fiscal year 2022Gross margin90.3%Operating margin−83,511.5%Net margin−169,771.2%Free cash flow margin−89,336.5%Fiscal year 2023Operating margin−314.8%Net margin−313.4%Free cash flow margin−239.3%Fiscal year 2024Operating margin−95.6%Net margin−96.6%Free cash flow margin−78.4%Fiscal year 2025Operating margin−171.6%Net margin−242.0%Free cash flow margin−152.4%
FY2021FY2022FY2023FY2024FY2025
Gross margin n/a 90.3% n/a n/a n/a
Operating margin n/a −83,511.5% −314.8% −95.6% −171.6%
Net margin n/a −169,771.2% −313.4% −96.6% −242.0%
Free cash flow margin n/a −89,336.5% −239.3% −78.4% −152.4%

Cash flow

The cash the business makes, what it reinvests, and what it hands back. Point at a year for the detail.
Operating cash flowCapital expenditureFree cash flow
Fiscal year 2021Operating cash flow−2.0Fiscal year 2022Operating cash flow−4.1Capital expenditure−0.2Free cash flow−4.3Fiscal year 2023Operating cash flow−6.0Capital expenditure−0.0Free cash flow−6.1Fiscal year 2024Operating cash flow−7.3Capital expenditure−0.1Free cash flow−7.3Fiscal year 2025Operating cash flow−9.3Capital expenditure−0.1Free cash flow−9.4
FY2021FY2022FY2023FY2024FY2025
Operating cash flow −2.0 −4.1 −6.0 −7.3 −9.3
Capital expenditure n/a −0.2 −0.0 −0.1 −0.1
Free cash flow n/a −4.3 −6.1 −7.3 −9.4
Growth

Balance sheet

What it holds against what it owes, at each year end. Point at a year for the detail.
Cash
Fiscal year 2021Cash1.4Shareholders’ equity−15.8Fiscal year 2022Cash11.4Shareholders’ equity11.0Fiscal year 2023Cash2.8Shareholders’ equity4.9Fiscal year 2024Cash1.1Shareholders’ equity2.6Fiscal year 2025Cash6.4Shareholders’ equity7.3
FY2021FY2022FY2023FY2024FY2025
Cash 1.4 11.4 2.8 1.1 6.4
Shareholders’ equity −15.8 11.0 4.9 2.6 7.3

In millions of USD, except per-share figures and ratios. Fiscal years, as last filed with the SEC.

Financial statements FY2025 · 10-K

Ratios

Percentages worked out from the filed figures; debt to equity in times. Fiscal years ending December, each column as last filed with the SEC.
Click a line to chart it
Fiscal year FY2021 31 Dec 2021 FY2022 31 Dec 2022 FY2023 31 Dec 2023 FY2024 31 Dec 2024 FY2025 31 Dec 2025
Margins
n/a 90.3% n/a n/a n/a
n/a −83,511.5% −314.8% −95.6% −171.6%
n/a −169,720.0% −312.6% −96.4% −241.2%
n/a −169,771.2% −313.4% −96.6% −242.0%
n/a −89,336.5% −239.3% −78.4% −152.4%
Spending
n/a 28,703.4% 58.0% 15.6% 22.4%
n/a 51,656.1% 268.1% 106.2% 160.9%
n/a 4,580.2% 0.9% 0.8% 1.0%
Returns
n/a −73.8% −163.5% −347.4% −204.9%
−435.3% −66.9% −96.5% −138.8% −136.0%
Balance and payout
908.3% 9.3% 40.9% 60.1% 33.6%